Evidence map›Paper›PMID 40205144›Full record

ReviewInfectious diseases and therapy2025

Optimal Timing of Vaccination: A Narrative Review of Integrating Strategies for COVID-19, Influenza, and Respiratory Syncytial Virus.

Paolo Bonanni, Jung Yeon Heo, Hitoshi Honda, Ping-Ing Lee, Aminatou Mouliom, Hoe Nam Leong, Maria Del Pilar Martin Matos, Rachel Dawson

Abstract readReview
In one paragraph

Review in Infectious diseases and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Paolo BonanniDepartment of Health Sciences, University of Florence, Florence, Italy.ORCID http://orcid.org/0000-0003-2875-3744
Jung Yeon HeoAjou University School of Medicine, Suwon, South Korea.ORCID http://orcid.org/0000-0002-6548-1939
Hitoshi HondaFujita Health University School of Medicine, Toyoake, Japan.ORCID http://orcid.org/0000-0002-4870-0730
Ping-Ing LeeDepartment of Pediatrics, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.ORCID http://orcid.org/0000-0002-7299-2825
Aminatou MouliomModerna, Inc., 325 Binney Street, Cambridge, MA, 02142, USA.ORCID http://orcid.org/0000-0001-9404-7325
Hoe Nam LeongRophi Clinic, Singapore, Singapore.
Maria Del Pilar Martin MatosModerna, Inc., 325 Binney Street, Cambridge, MA, 02142, USA. Maria.delPilarMartinMatos@modernatx.com.
Rachel DawsonModerna, Inc., 325 Binney Street, Cambridge, MA, 02142, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lower respiratory tract infections caused by SARS-CoV-2, influenza, and respiratory syncytial virus (RSV) cause a significant disease burden globally, despite the availability of effective vaccines. Certain populations, such as older adults (≥ 60 years) and individuals of all ages with particular comorbidities, are at increased risk for severe outcomes, including hospitalization and death. National administration schedules for available vaccines against respiratory viruses are not unified, and not all current guidelines are clear and directive, concerning the optimal timing of vaccination. Herein, we formulate an evidence-based position regarding the optimal timing of COVID-19, influenza, and RSV vaccination for older adults and individuals with chronic comorbidities, based on a synthesis of the literature and current guidelines. Vaccination impact and timing were found to be influenced by vaccinee risk factors, including age and comorbidities, and waning vaccine effectiveness and seasonal pathogen burden. Because COVID-19, influenza, and RSV display unique seasonal patterns within and between regions, local epidemiological surveillance of each virus is crucial for determining optimal vaccination timing and guidelines. To maximize the benefits of these respiratory virus vaccines, the timing of peak vaccine effectiveness and period of greatest risk for severe outcomes should be aligned. Thus, COVID-19, influenza, and other recommended vaccines given ahead of the start of the respiratory virus season (or other regionally appropriate time) and co-administered at a single, routine visit represent the optimal approach to protecting at-risk populations. More data will be required to establish the clinical benefit of additional RSV vaccine doses and whether these may be integrated within a seasonal schedule. Coordinated policy decisions that align with strain selection for new and annually reformulated vaccines would enable the timely raising of public health awareness, ultimately leading to enhanced vaccine uptake. Implementation strategies will require engagement of healthcare providers and strong, evidence-based public health recommendations for integrated vaccine schedules.

Indexed as

Co-administrationCOVID-19InfluenzaLower respiratory tract infectionOlder adultsPublic healthRespiratory syncytial virusRSVSARS-CoV-2Vaccination

Identifiers

PMID40205144
PMCPMC12084464

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.